TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration.
Eye (London, England)
View this publicationEye (London, England)
View this publicationFrontiers in immunology
View this publicationCardiovascular research
View this publicationNature communications
View this publicationScientific reports
View this publicationNeurology(R) neuroimmunology & neuroinflammation
View this publicationChemMedChem
View this publicationEye (London, England)
View this publicationCell reports
View this publicationPflugers Archiv : European journal of physiology
View this publication